NAMI - The National Alliance on Mental Illness

Antipsychotic Medicines for Children and Teens: A Review of the Antipsychotic Medicines for Children and Teens: A Review of the Research for Parents and Caregivers

NAMI's Report on Children and Psychotropic Medications
NAMI convened an expert work group in developing this report on Children and Psychotropic Medications. The report provides important perspectives on the need for sound clinical practice in child psychiatry and providing parents with information to make decisions in the best interest of their child.

Youth Suicide Increases

FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events

FDA Requires "Black Box" Warnings and Patient Medication Guide for Antidepressant Medications
News Brief - FDA's "Black Box" Warning for Antidepressants.

FDA Warning on ADHD Medications: NAMI's Talking Points
NAMI's response and talking points on the FDA's warning on ADHD Medications.

NAMI's Statement about the FDA "Black Box Warning" on Antidepressants

NAMI's statement before the FDA regarding the safety of anti-depression medication in children
A statement on the critically important issue of the safety and effectiveness of selective serotonin reuptake inhibitors (SSRIs) for children and adolescents with depression.

Learn More About Specific Medications for Children

Statement of Jim McNulty on Behalf of NAMI on Attention Deficit/Hyperactivity Disorders-Are Children Being Overmedicated Submitted to the Committee on Government Reform U.S. House of Representatives September 27, 2002

Medication for Children’s Treatment: What You Need to Know About Medications